BantingFG, BestCH, CollipJB, CampbellWR, FletcherAA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J, 1922; 12:141–146.
2.
BorgoñoCA, ZinmanB. Insulins: past, present, and future. Endocrinol Metab Clin N Am, 2012; 41:1–24.
3.
PolonskyKS, GivenBD, HirschL, ShapiroE T, TillilH, BeebeC, GallowayJA, FrankBH, KarrisonT, Van CauterE. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest, 1988; 81:435–441.
4.
SangerF. Chemistry of insulin; determination of the structure of insulin opens the way to greater understanding of life processes. Science, 1959; 129:1340–1344.
ColwellAR. Protamine insulin mixtures in the treatment of diabetes mellitus. N Y State J Med, 1947; 47:1103–1110.
7.
HimsworthHP. Protamine insulin and zinc protamine insulin. BMJ, 1937; 1:541–546.
8.
KrayenbuhlC, RosenbergT. Crystalline protamine insulin. Rep Steno Mem Hosp Nord Insulinlab, 1946; 1:60–73.
9.
Hallas-MøllerK. The lente insulins. Diabetes, 1956; 5:7–14.
10.
HirschI. Insulin analogs. N Engl J Med, 2005; 352:174–183.
11.
GargSK, MoserEG. How basal insulin analogs have changed diabetes care. Diabetes Technol Ther, 2011; 13,Suppl 1:S-1–S-4.
12.
SwitzerSM, MoserEG, RocklerBE, GargSK. Intensive insulin therapy in patients with type 1 diabetes mellitus. Endocrinol Metab Clin N Am, 2012; 41:89–104.
13.
RosskampRH, ParkG. Long-acting insulin analogs. Diabetes Care, 1999; 22:B109–B113.
14.
BerchtoldH, HilgenfeldR. Binding of phenol to R6 insulin hexamers. Biopolymers, 1999; 51:165–172.
15.
PorcellatiF, RossettiP, RicciNB, PampanelliS, TorloneE, CamposSH, AndreoliAM, BolliGB, FanelliCG. Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. Diabetes Care, 2007; 30:1261–1263.
16.
LeporeM, PampanelliS, FanelliC, PorcellatiF, BartocciL, Di VincenzoA, CordoniC, CostaE, BrunettiP, BolliGB. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes, 2000; 49:2142–2148.
17.
HeinemannL, LinkeschovaR, RaveK, HompeschB, SedlakM, HeiseT. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care, 2000; 23:644–649.
18.
ScholtzHE, PretoriusSG, WesselsDH, BeckerRH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia, 2005; 48:1988–1995.
19.
RosenstockJ, FonsecaV, McGillJB, RiddleM, HalleJP, HramiakI, JohnstonP, DavisM. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia, 2009; 52:1778–1788.
20.
RiddleMC, RosenstockJ, GerichJ. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 2003; 26:3080–3086.
21.
AshwellSG, GebbieJ, HomePD. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med, 2006; 23:46–52.
22.
MuchaGT, MerkelS, ThomasW, BantleJP. Fasting and insulin glargine in individuals with type 1 diabetes. Diabetes Care, 2004; 27:1209–1210.
23.
RosenstockJ, DaileyG, Massi-BenedettiM, FritscheA, LinZ, SalzmanA. Reduced hypoglycaemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care, 2005; 28:950–955.
24.
BockG, WutteA, KöhlerG, KorsatkoS, SemlitschB, PieberTR. Pharmacodynamics and pharmacokinetics of long-acting insulin analogues detemir and glargine after 7 days of use and after its first administration in subjects with type 1 diabetes [abstract]Diabetologia, 2008; 51:S390.
25.
KleinO, LyngeJ, EndahlL, DamholtB, NosekL, HeiseT. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab, 2007; 9:290–299.
26.
HeiseT, NosekL, RønnBB, EndahlL, HeinemannL, KapitzaC, DraegerE. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes, 2004; 53:1614–1620.
27.
RendellM, AkturkHK, TellaSH. Glarginesafety, diabetes and cancer. Expert Opin Drug Saf, 2013; 12:247–263.
28.
ShymkoRM, DumontE, DeMeytsP, DumontJE. Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding. Biochem J, 1999; 339:675–683.
29.
KurtzhalsP, SchäfferL, SørensenA, KristensenC, JonassenI, SchmidC, TrübT. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes, 2000; 49:999–1005.
ShuklaA, GrisouardJ, EhemannV, HermaniA, EnzmannH, MayerD. Analysis of signaling pathways relatedto cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer, 2009; 16:429–441.
32.
HemkensLG, GrouvenU, BenderR, GünsterC, GutschmidtS, SelkeGW, SawickiPT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia, 2009; 52:1732–1744.
33.
JonassonJM, LjungR, TalbäckM, HaglundB, GudbjörnsdòttirS, SteineckG. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia, 2009; 52:1745–1754.
34.
Colhoun HM; SDRN Epidemiology Group:. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 2009; 52:1755–1765.
35.
CurrieCJ, PooleCD, GaleEA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia, 2009; 52:1766–1777.
PocockSJ, SmeethL. Insulin glargine and malignancy: an unwarranted alarm. Lancet, 2009; 374:511–513.
38.
SmithU, GaleEAM. Does diabetes therapy influence the risk of cancer?Diabetologia, 2009; 52:1699–1708.
39.
OwenDR. Glargine and cancer: can we now suggest closure?Diabetes Care, 2012; 35:2426–2428.
40.
BoyleP. Northern European Database Study of Insulin and Cancer Risk. Presented at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, 2012.
41.
HabelLA. Results from Kaiser-Permanente collaboration. Presented at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, 2012.
42.
SturmerT. Cancer link with insulin—data from the U.S. and Northern Europe. Presented at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, 2012.
43.
BoyleP, KoechlinA, BonioM, RobertsonC, BolliG, RosenstockJ. Updated meta-analysis of cancer risk among users of insulin glargine. Presented at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, 2012.
44.
The ORIGIN Trial Investigators:. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med, 2012; 367:319–328.
45.
KeatingGM. Insulin detemir: a review of its use in the management of diabetes mellitus. Drugs, 2012; 72:2255–2287.
RotensteinLS, RanN, ShiversJP, YarchoanM, CloseKL. Opportunities and challenges for biosimilars: what's on the horizon in the global insulin market?Clin Diabetes, 2012; 30:138–150.
48.
HomeP. Biosimilars. Presented at the 71st Scientific Sessions of the American Diabetes Association, 2011San Diego, CA.
49.
U.S. Food and Drug Administration. Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Rockville, MD: U.S. Food and Drug Administration, 2012.
50.
Committee for Medicinal Products for Human Use: Guideline on Similar Biological Medicinal Products. CHMP/437/04 2005. 2005. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. 2013 July 30.
51.
CasadevallN, NatafJ, VironB, KoltaA, KiladjianJJ, Martin-DupontP, MichaudP, PapoT, UgoV, TeyssandierI, VaretB, MayeuxP. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med, 2002; 346:469–475.
52.
KalraS, UnnikrishnanAG, BaruahM, KalraB. Degludec insulin: a novel basal insulin. Indian J Endocrinol Metab, 2011; 15,Suppl:S12–S16.
53.
ZinmanB, FulcherG, RaoPV, ThomasN, EndahlLA, JohansenT, LindhR, LewinA, RosenstockJ, PingetM, MathieuC. Insulin degludec, ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet, 2011; 377:924–931.
54.
BirkelandKI, HomePD, WendischU, RatnerRE, JohansenT, EndahlLA, LybyK, JendleJH, RobertsAP, DeVriesJH, MeneghiniLF. Insulin degludec in type 1 diabetes: a randomized controlled trial of new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care, 2011; 34:661–665.
55.
HellerS, BuseJ, FisherM, GargS, MarreM, MerkerL, RenardE, Russell-JonesD, PhilotheouA, FranciscoAM, PeiH, BodeB. BEGIN Basal-Bolus Type 1 Trial Investigators: Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet, 2012; 379:1489–1497.
56.
GarberAJ, KingAB, Del PratoS, SreenanS, BalciMK, Muñoz-TorresM, RosenstockJ, EndahlLA, FranciscoAM, HollanderP. NN1250-3582 (BEGIN BB T2D) Trial Investigators: Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet, 2012; 379:1498–1507.
57.
FDA Briefing Document. NDA 203313 and NDA 203314. Insulin. Degludec and Insulin Degludec/Aspart. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. November8, 2012. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327015.pdf. 2013 June 27.
58.
SinhaVP, HoweyDC, KwangD, SoonW, ChoiSL, MaceKF. Single-dose pharmacokinetics (PK) and glucodynamics (GD) of the novel, long-acting basal insulin LY2605541 in healthy subjects [abstract]Diabetes, 2012; 61:A273.
59.
HeiseT, HoweyDC, SinhaVP, ChoiSL, MaceKF. Steady-state pharmacokinetics (PK) and glucodynamics (GD) of the novel-long-acting basal insulin LY2605541 dosed once daily (QD) in patients with type 2 diabetes mellitus (T2DM) [abstract]Diabetes, 2012; 61:A256.
60.
RosenstockJ, BergenstalRM, BlevinsTC, MorrowLA, PrinceMJ, QuY, SinhaVP, HoweyDC, JacoberSJ. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care, 2013; 36:522–528.
61.
BergenstalRM, RosenstockJ, ArakakiRF, PrinceMJ, QuY, SinhaVP, HoweyDC, JacoberSJ. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care, 2012; 35:2140–2147.
62.
SimonACR, DeVriesJH. The future of basal insulin supplementation. Diabetes Technol Ther, 2011; 13,Suppl 1:S-103–S-108.
63.
ChuJ. Smart Insulin: An Experimental Drug for Diabetes Dispenses Insulin in Response to Glucose Levels. October28, 2008. www.technologyreview.com/news/411110/smart-insulin/. 2013 July 30.
64.
Hoeg-JensenT, HavelundS, NielsenPK, MarkussenJ. Reversible insulin self-assembly under carbohydrate control. J Am Chem Soc, 2005; 127:6158–6159.
65.
KadishAH. A servomechanism for blood sugar control. Biomed Sci Instrum, 1963; 1:171–176.
66.
SkylerJS, PonderS, KrugerDF, MathesonD, ParkinCG. Is there a place for insulin pump therapy in your practice?Clin Diabetes, 2007; 25:50–56.
67.
FryA. Insulin delivery device technology 2012: where are we after 90 years?J Diabetes Sci Technol, 2012; 6:947–953.
68.
AgrawalP, WelshJB, KannardB, AskariS, YangQ, KaufmanFR. Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol, 2011; 5:1137–1141.
69.
ChoudharyP, ShinJ, WangY, EvansML, HammondPJ, KerrD, ShawJA, PickupJC, AmielSA. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care, 2011; 34:2023–2025.
70.
DanneT, KordonouriO, HolderM, HaberlandH, GolembowskiS, RemusK, BläsigS, WadienT, ZierowS, HartmannR, ThomasA. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther, 2011; 13:1129–1134.
71.
GargS, BrazgRL, BaileyTS, BuckinghamBA, SloverRH, KlonoffDC, ShinJ, WelshJB, KaufmanFR. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther, 2012; 14:205–209.
72.
BergenstalRM, KlonoffDC, GargSK, BodeBW, MeredithM, SloverRH, AhmannAJ, WelshJB, LeeSW, KaufmanFR. the ASPIRE In-Home Study Group. Threshold based insulin pump feedback for reduction of hypoglycemia. N Engl J Med, 2013; 369:224–232.
